Generics are becoming an increasingly lucrative market with good prospects for the future. However, a report by US market data provider BCC Research shows that this is also a bit of an exclusive club. The top four global generics manufacturers in 2009 – Teva, Sandoz, Mylan and Watson – accounted for 40% of the world market.
Teva increases its global position with acquisition of Ratiopharm
Home/Pharma News
|
Posted 10/09/2010
0
Post your comment
Teva, with an 18% market share in 2009, is reinforcing its global number one position with the recent acquisition of the 5th largest generic manufacturer, Ratiopharm. This move has increased both its global position and has propelled it to the number one position in Europe.
Teva's President and CEO, Mr Shlomo Yanai, commented that “increasing Teva's market share in Europe – a geography with tremendous potential for generics penetration – is an important pillar of our long-term growth strategy. With the acquisition of Ratiopharm we will become the leader in key European markets and we are well-positioned to become the leader in many other European markets in the near future".
Related article
Teva with ratiopharm market leader in European generics
References
BCC Research. Generic Drugs: The Global Market. Report Code: PHM009E, Published: July 2009
Teva Press Release. Teva Completes Acquisition of ratiopharm. 10 August 2010
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Coherus exits the biosimilars market with sale of Udenyca to Intas Pharmaceuticals
Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement
Related content
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Home/Pharma News Posted 15/01/2025
Coherus exits the biosimilars market with sale of Udenyca to Intas Pharmaceuticals
Home/Pharma News Posted 08/01/2025
Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement
Home/Pharma News Posted 20/11/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment